• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Arena Pharmaceuticals Announces Changes to Board of Directors

    2/16/21 8:30:00 AM ET
    $IVA
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email

    SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil, MD, has been appointed Chair of the Board. Additionally, Nawal Ouzren has been appointed as a new Board member.

    “These changes in our Board leadership will help position Arena for the growth we anticipate and mark an important inflection point in our progress,” said Amit D. Munshi, President and CEO of Arena. “Garry Neil has served on the Board for the past four years, providing exceptional leadership for our scientific direction. As a physician with extensive industry experience, his insight into successfully translating scientific discoveries into marketable drugs will shape our approach going forward.”

    Dr. Neil has served on our Board of Directors since February 2017. He serves as the Chief Scientific Officer of Cerecor, Inc., a publicly held biotechnology company focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with life altering diseases, a position he has held since Cerecor’s February 2020 merger with Aevi Genomic Medicine, Inc., a biotechnology company with the same focus, where Dr. Neil had served as Chief Scientific Officer since September 2013. Prior to joining Aevi Genomic Medicine, Dr. Neil was a Partner at Apple Tree Partners, a life science private equity firm, from September 2012 to September 2013, and held a number of senior positions in the pharmaceutical industry, including most recently as Corporate VP of Science & Technology at Johnson & Johnson from November 2007 to August 2012. Prior to these roles, Dr. Neil served as Group President at Johnson & Johnson Pharmaceutical Research and Development, VP of R&D at Merck KGaA/EMD Pharmaceuticals, and VP of Clinical Research at AstraZeneca and Astra Merck. Dr. Neil holds a BS from the University of Saskatchewan and an MD from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. Dr. Neil also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He served on the Board of GTx, Inc., a publicly traded biopharmaceutical company focused on cancer and other serious medical conditions, until its merger with Oncternal Therapeutics in March 2019. Dr. Neil is the Founding Chairman of TransCelerate Biopharma, Inc., a non-profit pharmaceuticals industry R&D consortium, and a past member of the TransCelerate Board. He also serves on the Board of the Reagan Udall Foundation and previously served on the Board of Foundation for the National Institutes of Health (NIH) and on the Science Management Review Board of the NIH. Dr. Neil is also the past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee and the PhRMA Foundation Board.

    “The appointment of Nawal Ouzren to the Board strengthens our Board leadership capabilities, and I am delighted to have the opportunity to work with her,” commented Dr. Neil, newly appointed Chair of the Arena Board of Directors. "Nawal brings broad based management experience including in operations and manufacturing, with both large and small biopharmaceutical companies. We are fortunate to have someone with her experience join the Board as we move toward commercial launch."

    Ms. Ouzren brings 20 years of leadership and expertise across a range of areas, including clinical development, operations, manufacturing, quality, and commercialization. She currently serves as Chief Executive Officer and Member of the Board at Sensorion SAS (ALSEN.PA), a publicly traded biotechnology company based in Montpellier, FR. Prior to joining Sensorion, she served as Group Vice President, Rare Genetic Diseases at Shire International GmbH. In that role she led a cross-functional organization including clinical development, R&D, and global marketing. Before Shire, Ms. Ouzren held various positions at Baxalta from 2014 to June 2016 when Baxalta was acquired by Shire. During her career, Ms. Ouzren also held roles of increasing responsibility across multiple functions at Baxter BioScience and General Electric. In addition to her Board role at Sensorion, Ms. Ouzren serves on the Board of Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company. Ms. Ouzren holds a Master of Science Degree in Chemical Engineering from the Université de Technologie de Compiègne, France.

    “Since 2016, we have continued to evolve the Board of Directors to provide effective guidance and oversight as the company has continued to grow. These new Board appointments will help steer Arena Pharmaceuticals toward our next stage of growth. I look forward to working with Garry and Nawal,” commented Mr. Munshi.

    About Arena Pharmaceuticals

    ARENA Pharmaceuticals is a team with a singular purpose – deliver our important medicines to patients.

    In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get our medicines to patients, and relentlessly execute until it’s done.

    ARENA - Care More. Act Differently.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements about Dr. Neil’s and Ms. Ouzren’s expected contributions, Arena’s purpose, work, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena’s filings with the Securities and Exchange Commission. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Get the next $IVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVA
    $ARNA

    CompanyDatePrice TargetRatingAnalyst
    Inventiva S.A.
    $IVA
    2/21/2025$10.00Buy
    TD Cowen
    Inventiva S.A.
    $IVA
    11/12/2024$3.00Neutral
    UBS
    Inventiva S.A.
    $IVA
    10/27/2023$12.00Buy
    Canaccord Genuity
    Inventiva S.A.
    $IVA
    5/31/2023$11.00Buy
    ROTH MKM
    Inventiva S.A.
    $IVA
    5/19/2023Sell → Buy
    Societe Generale
    Inventiva S.A.
    $IVA
    3/17/2023$27.00Buy
    Stifel
    Inventiva S.A.
    $IVA
    11/15/2022Buy → Sell
    Societe Generale
    Arena Pharmaceuticals Inc.
    $ARNA
    2/9/2022$120.00 → $100.00Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $IVA
    $ARNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      10/21/24 9:00:40 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      10/21/24 8:54:43 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Inventiva S.A.

      SC 13D/A - Inventiva S.A. (0001756594) (Subject)

      7/19/24 4:30:23 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    $ARNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Inventiva with a new price target

      TD Cowen initiated coverage of Inventiva with a rating of Buy and set a new price target of $10.00

      2/21/25 8:15:44 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Inventiva with a new price target

      UBS initiated coverage of Inventiva with a rating of Neutral and set a new price target of $3.00

      11/12/24 7:43:33 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Inventiva with a new price target

      Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00

      10/27/23 7:43:43 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    $ARNA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Inventiva S.A.

      SCHEDULE 13D/A - Inventiva S.A. (0001756594) (Subject)

      5/9/25 5:50:45 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/5/25 5:20:28 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/2/25 4:05:22 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    $ARNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IVA
    $ARNA
    Financials

    Live finance-specific insights

    See more
    • Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

      Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

      5/5/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

      Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of May 22, 2025. Shareholders are invited to participate in the Combined General Meeting that will be held on May 22, 2025 at 9 a.m. CEST at Hôtel Villa M, 24 – 30 Boulevard Pasteur, 75015 Par

      4/30/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

      ► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological endpoints, suggested better predictive accuracy than other diagnostic scores available including FIB4, FIBC3, ABC3D, NFS, ELF and MACK-3 ► The biomarker signatures suggested strong predictive accuracy, with AUROC values above 0.80 that may indicate high reliability in distinguishing responders from non-responders ► The analysis confirmed that histological response to lanifibranor could be assessed with non-invasive signatures based on blood mark

      4/24/25 4:01:23 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

      Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi

      5/5/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva reports its 2024 full year results and provides a business update

      Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

      3/26/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

      Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

      3/19/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    $ARNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Nova Tina Susan disposed of 20,843 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:24:43 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Fetzer Oliver disposed of 9,692 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:24:23 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gallahue Kieran disposed of 12,911 shares, closing all direct ownership in the company

      4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)

      3/11/22 4:23:59 PM ET
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    $ARNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Sensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent Director

      Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b

      4/2/25 1:30:00 AM ET
      $LBPH
      $ARNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

      Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.   Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH.   Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica

      12/16/24 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

      Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva's Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomized in the NATiV3 study evaluating lanifibranor for the treatment of noncirrhotic MASH, with completion of enrollment projected in 1H 2025.Appointment to the Board of Directors of Mark Pruzanski, MD,

      10/14/24 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care